Replies to post #47818 on Biotech Values

[rkrw]

Placebo response here as improvement in clinical response was 46%. 66 patients in high dose means 24 did well (36.4%). If you take out the 9 deaths your way, you get 24/57 or a 42% response, not quite as good as placebo. Give Paion the benefit of the doubt and say all 9 deaths would have been responders as they each got hit by busses on the way home from a successful rehab, you get a 50% response (33/66) vs 46% for placebo. Assume a generous 7/9 were responders and you get 46% vs 46%.

[ghmm]

Question Stroke Drugs in Trials -

For those companies with treatments beyond the 3-4 hour range why wouldn't they go after those outside the TPA treatment window? Is there anything approved for beyond this range?

The other concern I have (I follow Neurobiological a bit) is those companies with treatments beyond 3 hours is it more likely they get those patience in their trials and thus have a harder chance to get efficacy (even over placebo) if in fact the treatment window is not quite as big as they think it is for their drug?